Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

PubWeight™: 5.95‹?› | Rank: Top 1%

🔗 View Article (PMID 10561349)

Published in J Clin Oncol on September 01, 1999

Authors

P B Chapman1, L H Einhorn, M L Meyers, S Saxman, A N Destro, K S Panageas, C B Begg, S S Agarwala, L M Schuchter, M S Ernstoff, A N Houghton, J M Kirkwood

Author Affiliations

1: Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Articles citing this

(truncated to the top 100)

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 4.60

Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21

MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med (2012) 1.93

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66

Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids (2011) 1.45

Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg (2013) 1.44

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One (2014) 1.42

Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One (2013) 1.34

Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21

Mucosal melanomas: a case-based review of the literature. Oncologist (2010) 1.20

A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One (2010) 1.17

Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One (2014) 1.16

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother (2011) 1.10

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs (2012) 1.09

Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol (2012) 1.08

Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer (2009) 1.05

Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02

Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res (2006) 1.01

Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01

Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis (2013) 1.00

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer (2010) 1.00

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99

Anorectal melanoma. Clin Colon Rectal Surg (2011) 0.99

Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer (2000) 0.98

A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res (2009) 0.98

Anorectal melanoma. Clin Colon Rectal Surg (2009) 0.97

Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol (2010) 0.97

Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. J Biol Chem (2014) 0.96

Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. PLoS One (2016) 0.95

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer (2010) 0.95

Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res (2009) 0.95

Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol (2008) 0.93

Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist (2010) 0.92

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer (2003) 0.92

The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am (2009) 0.92

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes (2012) 0.92

Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther (2014) 0.92

A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia (2009) 0.91

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res (2012) 0.91

A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs (2006) 0.90

Merlin is a negative regulator of human melanoma growth. PLoS One (2012) 0.89

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest New Drugs (2005) 0.89

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer (2011) 0.88

Molecular markers of tumor progression in melanoma. Curr Genomics (2009) 0.88

Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer (2016) 0.87

Single-agent interleukin-2 in the treatment of metastatic melanoma. Curr Oncol (2007) 0.85

A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother (2014) 0.84

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer (2006) 0.83

Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr Mol Med (2011) 0.83

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs (2001) 0.83

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol (2012) 0.82

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemp Oncol (Pozn) (2013) 0.82

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Invest New Drugs (2011) 0.81

Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity. J Immunol Res (2014) 0.81

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer (2010) 0.81

Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag (2016) 0.81

Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol (2013) 0.80

Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A (2004) 0.80

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80

Paraneoplastic granulocytosis in metastatic melanoma. Melanoma Res (2010) 0.80

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget (2015) 0.80

Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression. Transl Oncol (2015) 0.79

Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol (2012) 0.79

Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World J Surg Oncol (2012) 0.79

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. Int J Cancer (2013) 0.79

Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol (2013) 0.79

Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol (2010) 0.79

Low back pain as the presenting sign in a patient with primary extradural melanoma of the thoracic spine--a metastatic disease 17 years after complete surgical resection. World J Surg Oncol (2011) 0.79

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacol Res Perspect (2015) 0.78

Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. J Cancer Res Clin Oncol (2007) 0.78

Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg (2012) 0.78

Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One (2015) 0.77

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. J Transl Med (2010) 0.77

Predictive factors for immunotherapy in melanoma. Ann Transl Med (2015) 0.77

A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol (2006) 0.77

cfDNA analysis from blood in melanoma. Ann Transl Med (2015) 0.77

Identifying novel molecular structures for advanced melanoma by ligand-based virtual screening. J Chem Inf Model (2009) 0.77

An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immun (2008) 0.77

Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. Br J Cancer (2013) 0.77

A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. J Med Case Rep (2010) 0.76

The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncol Lett (2012) 0.76

Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. J Immunother Cancer (2014) 0.76

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Br J Cancer (2007) 0.76

Articles by these authors

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Racial differences in the treatment of early-stage lung cancer. N Engl J Med (1999) 9.65

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93

Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med (1977) 4.91

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

The influence of hospital volume on survival after resection for lung cancer. N Engl J Med (2001) 4.83

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics (1983) 4.51

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making (1985) 4.47

Drugs five years later. Cisplatin. Ann Intern Med (1984) 3.69

Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst (2001) 3.65

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med (1987) 3.52

Biases in the assessment of diagnostic tests. Stat Med (1987) 3.48

Leptomeningeal metastases in the MRI era. Neurology (2010) 3.48

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30

Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27

Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst (1996) 3.23

Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA (2000) 3.18

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol (2001) 3.06

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1992) 2.90

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73

Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65

Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med (1990) 2.64

Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44

Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. J Clin Oncol (2001) 2.43

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37

A general regression methodology for ROC curve estimation. Med Decis Making (1988) 2.37

A treatment allocation procedure for sequential clinical trials. Biometrics (1980) 2.26

Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25

Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20

Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19

Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13

No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11

Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol (1996) 2.06

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol (1998) 2.03

Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02

Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med (1989) 1.98

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1998) 1.94

Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92

Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. Semin Oncol (1979) 1.91

Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg (1996) 1.91

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol (1992) 1.87

Late relapse of testicular cancer. J Clin Oncol (1995) 1.87

Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85

The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer (1984) 1.85

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol (1992) 1.84

Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81

Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer (1980) 1.79

High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol (1996) 1.77

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer (2006) 1.77

Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol (1998) 1.74

Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73

Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest (1991) 1.72

Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol (1998) 1.72

Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1997) 1.70

Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol (1997) 1.70

Testing for fetal pulmonary maturity: ROC analysis involving covariates, verification bias, and combination testing. Med Decis Making (1990) 1.68

Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol (1989) 1.68

Treatment allocation methods in clinical trials: a review. Stat Med (1985) 1.67

Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65

Stroke in patients with cancer: incidence and etiology. Neurology (2004) 1.65

Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res (2001) 1.64

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59

Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol (1999) 1.59

Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59

Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58

The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58

Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer (1997) 1.57

Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med (1979) 1.57

Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol (1997) 1.55

Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol (1994) 1.55

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer (1993) 1.52

A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52

Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol (1994) 1.51

Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol (1993) 1.51

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51

Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol (1988) 1.49

Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med (1983) 1.48

Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46

Metastatic patterns of choroidal melanoma. Cancer (1974) 1.45